Project description
Gene therapy for Alzheimer’s disease
Despite extensive research into Alzheimer’s disease (AD), current treatment options are limited and only achieve a slight delay in the clinical decline. Therefore, novel approaches are needed that halt cognitive decline and disease progression. Funded by the Marie Skłodowska-Curie Actions programme, the BEndTarG project proposes an alternative intervention that aims to clear the amyloid-beta plaques, one of the hallmarks of AD. Researchers will develop nanocarriers engineered to specifically target brain endothelial cells and capable of reaching the blood-brain barrier. The nanocarriers will contain genes that enhance amyloid-beta clearance as a novel gene therapy strategy for AD.
Fields of science
Programme(s)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Funding Scheme
HORIZON-AG-UN - HORIZON Unit GrantCoordinator
08028 Barcelona
Spain
See on map